Shorter useful life of DIFICLIR sales rights and increased amortization burden

「The marketing rights for Dificlir, a product held by the Company’s subsidiary Tillotts Pharma AG, are amortized based on an estimated useful life corresponding to the period over which economic benefits are expected to arise. However, due to the increased likelihood of generic products entering the market, the useful life has been shortened and the change will apply prospectively. As a result, operating profit, ordinary profit and interim net income before income taxes and other adjustments for the current interim consolidated accounting period each decreased by ¥779.854 million.」